ALKERMES PLC (ALKS) Stock Price, Quote, News and Overview
NASDAQ:ALKS - Nasdaq - IE00B56GVS15 - Common Stock - Currency: USD
ALKS Quote, Performance and Key Statistics
34.35
-0.3 (-0.87%)
The current stock price of ALKS is 34.35 USD. In the past month the price increased by 9.43%. In the past year, price increased by 17.44%.
ALKS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About ALKS
Company Profile
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 2,100 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
Company Info
ALKERMES PLC
Connaught House, 1 Burlington Road, Dublin 4
DUBLIN DUBLIN DUBLIN 4 IE
CEO: Richard F. Pops
Employees: 2100
Company Website: https://www.alkermes.com/
Investor Relations: https://investor.alkermes.com
Phone: 35317728000
ALKERMES PLC / ALKS FAQ
What is the stock price of ALKERMES PLC today?
The current stock price of ALKS is 34.35 USD. The price decreased by -0.87% in the last trading session.
What is the ticker symbol for ALKERMES PLC stock?
The exchange symbol of ALKERMES PLC is ALKS and it is listed on the Nasdaq exchange.
On which exchange is ALKS stock listed?
ALKS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALKERMES PLC stock?
21 analysts have analysed ALKS and the average price target is 37.16 USD. This implies a price increase of 8.17% is expected in the next year compared to the current price of 34.35. Check the ALKERMES PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALKERMES PLC worth?
ALKERMES PLC (ALKS) has a market capitalization of 5.59B USD. This makes ALKS a Mid Cap stock.
How many employees does ALKERMES PLC have?
ALKERMES PLC (ALKS) currently has 2100 employees.
What are the support and resistance levels for ALKERMES PLC (ALKS) stock?
ALKERMES PLC (ALKS) has a support level at 34.32 and a resistance level at 35.9. Check the full technical report for a detailed analysis of ALKS support and resistance levels.
Is ALKERMES PLC (ALKS) expected to grow?
The Revenue of ALKERMES PLC (ALKS) is expected to decline by -7.55% in the next year. Check the estimates tab for more information on the ALKS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ALKERMES PLC (ALKS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALKS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALKS, evaluating the profitability, health, valuation and growth aspects
- ALKERMES PLC (ALKS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALKERMES PLC (ALKS) Sales and EPS estimates to see what analysts future expectations are.
- ALKERMES PLC (ALKS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALKERMES PLC (ALKS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALKERMES PLC (ALKS) Stock Chart to make your own analysis
- ALKERMES PLC (ALKS) Latest news and press-releases to stay up to date.
Does ALKERMES PLC (ALKS) stock pay dividends?
ALKS does not pay a dividend.
When does ALKERMES PLC (ALKS) report earnings?
ALKERMES PLC (ALKS) will report earnings on 2025-04-29, before the market open.
What is the Price/Earnings (PE) ratio of ALKERMES PLC (ALKS)?
The PE ratio for ALKERMES PLC (ALKS) is 11.84. This is based on the reported non-GAAP earnings per share of 2.9 and the current share price of 34.35 USD. Check the full fundamental report for a full analysis of the valuation metrics for ALKS.
What is the Short Interest ratio of ALKERMES PLC (ALKS) stock?
The outstanding short interest for ALKERMES PLC (ALKS) is 7.26% of its float. Check the ownership tab for more information on the ALKS short interest.
ALKS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ALKS. When comparing the yearly performance of all stocks, ALKS is one of the better performing stocks in the market, outperforming 86.6% of all stocks.
ALKS Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ALKS. Both the health and profitability get an excellent rating, making ALKS a very profitable company, without any liquidiy or solvency issues.
ALKS Financial Highlights
Over the last trailing twelve months ALKS reported a non-GAAP Earnings per Share(EPS) of 2.9. The EPS increased by 104.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 23.57% | ||
| ROA | 17.86% | ||
| ROE | 25.06% | ||
| Debt/Equity | 0 |
ALKS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to ALKS. The Buy consensus is the average rating of analysts ratings from 21 analysts.
For the next year, analysts expect an EPS growth of -36.06% and a revenue growth -7.55% for ALKS